HUP0100285A2 - Protein kináz C inhibitorok alkalmazása daganatellenes szerek és sugárterápia klinikai hatékonyságának javítására szolgáló gyógyászati készítmények előállítására - Google Patents

Protein kináz C inhibitorok alkalmazása daganatellenes szerek és sugárterápia klinikai hatékonyságának javítására szolgáló gyógyászati készítmények előállítására

Info

Publication number
HUP0100285A2
HUP0100285A2 HU0100285A HUP0100285A HUP0100285A2 HU P0100285 A2 HUP0100285 A2 HU P0100285A2 HU 0100285 A HU0100285 A HU 0100285A HU P0100285 A HUP0100285 A HU P0100285A HU P0100285 A2 HUP0100285 A2 HU P0100285A2
Authority
HU
Hungary
Prior art keywords
radiation therapy
inhibitors
protein kinase
enhance
clinical efficacy
Prior art date
Application number
HU0100285A
Other languages
English (en)
Inventor
Michael R. Jirousek
Lawrence E. Stramm
Douglas Kirk Ways
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP0100285A2 publication Critical patent/HUP0100285A2/hu
Publication of HUP0100285A3 publication Critical patent/HUP0100285A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya protein kináz C inhibitorok alkalmazásadaganatellenes szerek és sugárterápia klinikai hatékonyságánakjavítására szolgáló gyógyászati készítmények előállítására. Atalálmány szerinti alkalmazás tekintetében előnyösek a protein kináz C<-izozim szelektív PKC inhibitorok, különösen előnyös az (S)-3,4-N,N'-1,1'-((2<-etoxi)-3<'(O)-4<'-(N,N-dimetil-amino)-bután)-bisz(3,3'-indolil))-1(H)-pirrol-2,5-dion vagy sói. Az ilyen PKCinhibitorok a daganatellenes szerek és a sugárterápia klinikaihatékonyságát együttes alkalmazás esetén fokozzák. Az együttesalkalmazás lehet a daganatellenes szerek vagy sugárterápiaalkalmazását megelőző, azzal egyidejű vagy azt követő alkalmazás. Ó
HU0100285A 1996-05-01 1997-05-01 Use of protein kinase c inhibitors to enhance the the clinical efficacy of oncolytic agents and radiation therapy HUP0100285A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1665896P 1996-05-01 1996-05-01
US08/841,738 US6232299B1 (en) 1996-05-01 1997-04-30 Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
PCT/US1997/007801 WO1997040842A1 (en) 1996-05-01 1997-05-01 Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy

Publications (2)

Publication Number Publication Date
HUP0100285A2 true HUP0100285A2 (hu) 2001-09-28
HUP0100285A3 HUP0100285A3 (en) 2003-05-28

Family

ID=26688914

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100285A HUP0100285A3 (en) 1996-05-01 1997-05-01 Use of protein kinase c inhibitors to enhance the the clinical efficacy of oncolytic agents and radiation therapy

Country Status (15)

Country Link
US (3) US6232299B1 (hu)
EP (1) EP0914135A4 (hu)
JP (1) JP2000510828A (hu)
KR (1) KR20000065223A (hu)
AU (1) AU718098B2 (hu)
BR (1) BR9710704A (hu)
CA (1) CA2253263A1 (hu)
CZ (1) CZ344398A3 (hu)
EA (1) EA199800971A1 (hu)
HU (1) HUP0100285A3 (hu)
IL (1) IL126768A0 (hu)
NO (1) NO985065L (hu)
NZ (1) NZ332563A (hu)
PL (1) PL330862A1 (hu)
WO (1) WO1997040842A1 (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
PT1478358E (pt) 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
JP2007511203A (ja) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
DE602004010407T2 (de) 2003-07-23 2008-10-16 Bayer Pharmaceuticals Corp., West Haven Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
AU2004282219C1 (en) * 2003-10-15 2009-12-17 Osi Pharmaceuticals, Inc. Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
SG163576A1 (en) 2004-04-02 2010-08-30 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
US20060228734A1 (en) * 2005-03-18 2006-10-12 Applera Corporation Fluid processing device with captured reagent beads
WO2006108270A1 (en) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
US20080214521A1 (en) * 2005-08-09 2008-09-04 Martin Schuler Sensitization of Drug-Resistant Lung Caners to Protein Kinase Inhibitors
CA2622867A1 (en) 2005-09-16 2007-03-22 Schering Corporation Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2009025847A2 (en) * 2007-08-21 2009-02-26 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
EP2050441A1 (en) * 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
US20090269773A1 (en) * 2008-04-29 2009-10-29 Nodality, Inc. A Delaware Corporation Methods of determining the health status of an individual
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
WO2010006291A1 (en) 2008-07-10 2010-01-14 Nodality, Inc. Methods for diagnosis, prognosis and treatment
US8399206B2 (en) * 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2010123792A1 (en) 2009-04-20 2010-10-28 Osi Pharmaceuticals, Inc. Preparation of c-pyrazine-methylamines
EP2427192A1 (en) * 2009-05-07 2012-03-14 OSI Pharmaceuticals, LLC Use of osi-906 for treating adrenocortical carcinoma
US20100297676A1 (en) * 2009-05-20 2010-11-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
SG192669A1 (en) 2011-02-11 2013-09-30 Glaxosmithkline Ip Dev Ltd Cathepsin c inhibitors
WO2012173841A1 (en) * 2011-06-07 2012-12-20 Dana-Farber Cancer Institute, Inc. Biomarker for pkc-iota activity and methods of using same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937232A (en) 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
SK278989B6 (sk) 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US4990519A (en) 1988-10-24 1991-02-05 Merrell Dow Pharmaceuticals Method of using quinolyloxazole-2-ones as proteinkinase C inhibitors
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5344841A (en) * 1990-11-02 1994-09-06 Sphinx Pharmaceuticals Corporation Bis-(hydroxylakylamino)-anthraquinone inhibitors of protein kinase C
US5141957A (en) 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
US5204370A (en) 1990-11-05 1993-04-20 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C
JPH06510280A (ja) * 1991-08-22 1994-11-17 スフィンクス・ファーマスーティカルズ・コーポレーション タンパクキナーゼｃ阻害および新規化合物バラノール
US5216014A (en) 1991-09-10 1993-06-01 Sphinx Pharmaceuticals Corporation Furo-coumarinsulfonamides as protein kinase C inhibitors
US5270310A (en) 1991-12-13 1993-12-14 Sphinx Pharmaceuticals Corporation N-aminoalkyl amide inhibitors of protein kinase C
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
CA2174431C (en) 1993-10-18 2005-12-06 Tomas Hudlicky Synthesis of sphingosines
DK0657411T3 (da) 1993-12-07 1999-11-15 Lilly Co Eli Forbedret syntese af bisindolylmaleimider
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
DK0817627T3 (da) * 1993-12-23 2005-06-06 Lilly Co Eli Inhibitorer af proteinkinase C
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
US5481003A (en) 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5432198A (en) * 1994-08-18 1995-07-11 Sphinx Pharmaceuticals Corporation Vicinal-substituted carbocyclic compounds as therapeutic agents
US5616577A (en) 1994-08-25 1997-04-01 Smithkline Beecham Corporation Protein Kinase C inhibitor

Also Published As

Publication number Publication date
IL126768A0 (en) 1999-08-17
NO985065D0 (no) 1998-10-30
EP0914135A4 (en) 2001-01-24
NZ332563A (en) 2000-08-25
WO1997040842A1 (en) 1997-11-06
AU3000297A (en) 1997-11-19
PL330862A1 (en) 1999-06-07
KR20000065223A (ko) 2000-11-06
JP2000510828A (ja) 2000-08-22
CA2253263A1 (en) 1997-11-06
CZ344398A3 (cs) 1999-07-14
AU718098B2 (en) 2000-04-06
US20010001791A1 (en) 2001-05-24
EA199800971A1 (ru) 1999-04-29
US6232299B1 (en) 2001-05-15
US6288053B1 (en) 2001-09-11
BR9710704A (pt) 1999-08-17
HUP0100285A3 (en) 2003-05-28
US6486179B2 (en) 2002-11-26
NO985065L (no) 1998-12-28
EP0914135A1 (en) 1999-05-12

Similar Documents

Publication Publication Date Title
HUP0100285A2 (hu) Protein kináz C inhibitorok alkalmazása daganatellenes szerek és sugárterápia klinikai hatékonyságának javítására szolgáló gyógyászati készítmények előállítására
DK0574457T3 (da) Antiviral nucleosidkombination
NO943669L (no) Topisk administrering av toremifen og dens metabolitter
EE200000794A (et) Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis
EE05424B1 (et) Asendatud asaindooloksoatseetpiperasiini derivaadid, neid sisaldav ravimpreparaat ning nende kasutamine ravis
NO974694L (no) Farmasöytisk preparat som inneholder N-fosfonoglycin-derivater for å inhibere vekst av cancer og virus
BRPI0415649A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
TR199500832A2 (tr) Benzimidazol türevleri ve bunlarin medikal terapide kullanimi ve bunlari iceren farmasötik formülasyonlar.
HUP0004300A2 (hu) (S)-N-Etil-3-[1-(dimetil-amino)-etil]-N-metil-fenil-karbamátot és antioxidánst tartalmazó gyógyszerkészítmény
HUP0104696A2 (hu) 5HT1 receptor agonistákat és metoklopramidot tartalmazó gyógyszerkészítmény migrén kezelésére
HUP0303927A2 (hu) Anti-angiogén ágensek és TNF-alfa alkalmazása kombinációs kezelésre
NO20004419L (no) Ny anvendelse
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
DE60124387D1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
BR9814419A (pt) &#34;combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas&#34;
CL2004000877A1 (es) Combinacion farmaceutica que comprende 8a) melatonina y agonistas de la melatonina, y nicotina y agonistas receptores de nicotina; kit farmaceutico, y; uso en el tratamiento de insomnio, dificultades cognitivas y dificultades de memoria; kit farmaceu
NO970178D0 (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
ATE218881T1 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin
TR199801439T2 (xx) Herpes simpleks enfeksiyonlar�n�n kombine terapisinde n�kleosit analoglar�.
BRPI0408518A (pt) terapia combinada compreendendo nemorubicin e um inibidor de ciclooxigenase-2
FR2827861B1 (fr) Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie
HUP9901935A2 (hu) Gyógyszerek és terápiás szerek és más glikozaminoglikánok (GAG) dózisainak célbajuttatására alkalmas dóziskészlet
TR199801728A2 (xx) Bir ilac�n �retimi i�in sodyum-hidrojen-de�i�tiricisi �nleyicilerinin kullan�m�.
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
ITRM910155A0 (it) Preparati farmaceutici per la terapia dei tumori contenenti colchicina come principio attivo e metodi per l&#39;impiego degli stessi.